BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8. [PMID: 10086436 DOI: 10.1001/jama.281.11.1014] [Cited by in Crossref: 331] [Cited by in F6Publishing: 350] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhou X, Fang G, Xie Y, Wei A, Huang F. Safety Evaluation of Antituberculosis Drugs During Pregnancy: A Systematic Review and Meta-Analysis. Front Surg 2022;9:871321. [DOI: 10.3389/fsurg.2022.871321] [Reference Citation Analysis]
2 Alvarez GG, Pease C, Menzies D. Chapter 6: Tuberculosis preventive treatment in adults. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 2022;6:77-86. [DOI: 10.1080/24745332.2022.2039498] [Reference Citation Analysis]
3 Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, Al-Abri S, Allen DM, Balcells ME, Garcia-Basteiro AL, Cambau E, Chaisson RE, Chee CBE, Dalcolmo MP, Denholm JT, Erkens C, Esposito S, Farnia P, Friedland JS, Graham S, Hamada Y, Harries AD, Kay AW, Kritski A, Manga S, Marais BJ, Menzies D, Ng D, Petrone L, Rendon A, Silva DR, Schaaf HS, Skrahina A, Sotgiu G, Thwaites G, Tiberi S, Tukvadze N, Zellweger JP, D Ambrosio L, Centis R, Ong CWM. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 2022;26:190-205. [PMID: 35197159 DOI: 10.5588/ijtld.21.0753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
4 Xiong Y, Wei J, Cai Y, Zhang Y, Feng L, Zhang Y, Bharti P. Analysis of the Research Hotspot of Drug Treatment of Tuberculosis: A Bibliometric Based on the Top 50 Cited Literatures. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/9542756] [Reference Citation Analysis]
5 Brown MR, Schult RF. Isoniazid. Reference Module in Biomedical Sciences 2022. [DOI: 10.1016/b978-0-12-824315-2.00121-4] [Reference Citation Analysis]
6 Saini V, Goyal A, Kumar A. Isoniazid: An Exploratory Review. Asian J Org Med Chem 2022;7:1-10. [DOI: 10.14233/ajomc.2022.ajomc-p373] [Reference Citation Analysis]
7 Lai EC, Liang HY, Huang YC, Huang WI, Chao PH, Chen WW, Weng MY. Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. Sci Rep 2021;11:18013. [PMID: 34504225 DOI: 10.1038/s41598-021-97444-8] [Reference Citation Analysis]
8 Dodani SK, Nasim A, Aziz T, Naqvi A. The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country. Transpl Infect Dis 2021;:e13709. [PMID: 34331355 DOI: 10.1111/tid.13709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Padmapriyadarsini C, Sekar L, Reddy D, Chitra A, Poornagangadevi N, Selvaraj M, Bhavani PK, Mothi SN, Nandagopal K, Vennila S, Tamizhselvan M, Maheshmanisha J, Agarwal U, Rewari BB, Swaminathan S. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. Indian J Med Res 2020;152:648-55. [PMID: 34145105 DOI: 10.4103/ijmr.IJMR_1582_18] [Reference Citation Analysis]
10 Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park Y, Choi YK, Phuong NTT, Shin JG; Center for Personalized Precision Medicine of Tuberculosis. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. J Clin Pharmacol 2021. [PMID: 34157153 DOI: 10.1002/jcph.1931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Abbasi NM, Xiao Y, Peng L, Duo Y, Wang L, Zhang L, Wang B, Zhang H. Recent Advancement for the Synthesis of MXene Derivatives and Their Sensing Protocol. Adv Mater Technol 2021;6:2001197. [DOI: 10.1002/admt.202001197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Cybulski DJ, White BK. Fatal Isoniazid Hepatotoxicity in the Deployed Environment. Mil Med 2021;186:619-22. [PMID: 33128555 DOI: 10.1093/milmed/usaa414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer 2021;9:e001664. [PMID: 33782108 DOI: 10.1136/jitc-2020-001664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 51] [Cited by in F6Publishing: 61] [Article Influence: 51.0] [Reference Citation Analysis]
15 Kandemir B, Duman I, Durduran Y, Metin Akcan O, Selver MB, Pekcan S. Unnoticed Adverse Effect of Isoniazid during Childhood Tuberculosis Preventive Treatment: Hyperuricemia. Journal of Pediatric Infectious Diseases 2021;16:116-21. [DOI: 10.1055/s-0041-1724022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel) 2021;10:390. [PMID: 33807700 DOI: 10.3390/antiox10030390] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 18.0] [Reference Citation Analysis]
17 Dodani S, Nasim A, Aziz T, Naqvi A. The Efficacy of Isoniazid Prophylaxis in Renal Transplant Recipients in a High TB Burden Country.. [DOI: 10.1101/2021.02.28.21252563] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lei S, Gu R, Ma X. Clinical perspectives of isoniazid-induced liver injury. Liver Research 2021;5:45-52. [DOI: 10.1016/j.livres.2021.02.001] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Taylor TH, Ibrahim D, Lewis JH. Tuberculosis of the Liver, Biliary Tract, and Pancreas. Tuberculosis and Nontuberculous Mycobacterial Infections 2021. [DOI: 10.1128/9781555817138.ch25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Manno RL, Liebowitz JE. Rheumatology. Geriatrics for Specialists 2021. [DOI: 10.1007/978-3-030-76271-1_18] [Reference Citation Analysis]
21 Shamseddeen H, Vilar-Gomez E, Chalasani N, Myers RP, Subramanian GM, Shlevin HH, Allgood AE, Orman ES. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. Drug Saf 2020;43:281-90. [PMID: 31907854 DOI: 10.1007/s40264-019-00896-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Crit Rev Oncol Hematol 2021;157:103127. [PMID: 33161366 DOI: 10.1016/j.critrevonc.2020.103127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Singh AK, Verma S, Kumar-M P, Soni H, Sharma S, Patil A, Sharma V. Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis.Expert Rev Clin Pharmacol. 2020;13:1253-1262. [PMID: 33043729 DOI: 10.1080/17512433.2020.1835468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhu J, Lu J, Tung HC, Liu K, Li J, Grant DM, Xie W, Ma X. Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD+ in the Liver. Drug Metab Dispos 2020;48:1372-9. [PMID: 33020065 DOI: 10.1124/dmd.120.000139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Dorjee K, Topgyal S, Dorjee C, Tsundue T, Namdol T, Tsewang T, Nangsel T, Lhadon D, Choetso T, Dawa T, Phentok T, DeLuca AN, Tsering L, Phunkyi D, Sadutshang TD, J Bonomo E, Paster Z, Chaisson RE. High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children. Clin Infect Dis 2019;69:760-8. [PMID: 30462191 DOI: 10.1093/cid/ciy987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
26 Liang W, Ren H, Li Y, Qiu H, Ye BC. A robust electrochemical sensing based on bimetallic metal-organic framework mediated Mo2C for simultaneous determination of acetaminophen and isoniazid. Anal Chim Acta 2020;1136:99-105. [PMID: 33081955 DOI: 10.1016/j.aca.2020.08.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
27 Imam F, Sharma M, Khayyam KU, Khan MR, Ali MD, Qamar W. Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India. Saudi Pharm J 2020;28:641-7. [PMID: 32550793 DOI: 10.1016/j.jsps.2020.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Bracchi M, van Halsema C, Post F, Awosusi F, Barbour A, Bradley S, Coyne K, Dixon-Williams E, Freedman A, Jelliman P, Khoo S, Leen C, Lipman M, Lucas S, Miller R, Seden K, Pozniak A. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med 2019;20 Suppl 6:s2-s83. [PMID: 31152481 DOI: 10.1111/hiv.12748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Adeniji SE, Uba S, Uzairu A. Quantitative structure–activity relationship and molecular docking of 4-Alkoxy-Cinnamic analogues as anti-mycobacterium tuberculosis. Journal of King Saud University - Science 2020;32:67-74. [DOI: 10.1016/j.jksus.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
30 Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020;20:318-29. [PMID: 31866327 DOI: 10.1016/S1473-3099(19)30575-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
31 Loureiro RB, Maciel ELN, Caetano R, Peres RL, Fregona G, Golub JE, Braga JU. Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil. PLoS One 2019;14:e0225197. [PMID: 31725786 DOI: 10.1371/journal.pone.0225197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Methanol and diethyl stem bark extracts of Harungana madagascariensis blunt acetaminophen-induced liver damage in rats through its anti-oxidant property. Savannah Vet J 2019. [DOI: 10.36759/svj.2019.032] [Reference Citation Analysis]
33 Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis 2018;22:1344-9. [PMID: 30355415 DOI: 10.5588/ijtld.18.0035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
34 Noh CS, Kim HI, Choi H, Kim Y, Kim CH, Choi JH, Hyun IG, Baek MS. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. Respir Med 2019;157:52-8. [PMID: 31522030 DOI: 10.1016/j.rmed.2019.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
35 Wyndham-Thomas C, Dirix V, Goffard JC, Henrard S, Wanlin M, Callens S, Mascart F, Van Vooren JP. 2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients. Acta Clin Belg 2019;74:242-51. [PMID: 30036162 DOI: 10.1080/17843286.2018.1494669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Zhang Y, Jiang X, Zhang J, Zhang H, Li Y. Simultaneous voltammetric determination of acetaminophen and isoniazid using MXene modified screen-printed electrode. Biosensors and Bioelectronics 2019;130:315-21. [DOI: 10.1016/j.bios.2019.01.043] [Cited by in Crossref: 146] [Cited by in F6Publishing: 156] [Article Influence: 48.7] [Reference Citation Analysis]
37 Indumathi CK, Sethuraman A, Jain S, Krishnamurthy S. Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. Indian J Pediatr 2019;86:229-32. [PMID: 30515702 DOI: 10.1007/s12098-018-2812-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Repossi A, Bothamley G. Tuberculosis in pregnancy and the elderly. Tuberculosis. [DOI: 10.1183/2312508x.10021917] [Reference Citation Analysis]
39 Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health 2018;3:e001135. [PMID: 30364389 DOI: 10.1136/bmjgh-2018-001135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hatzenbuehler LA, Starke JR. Treatment of tuberculosis infection in children. Expert Rev Anti Infect Ther 2018;16:695-708. [PMID: 30132364 DOI: 10.1080/14787210.2018.1513324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Jung BH, Park JI, Lee SG. Urgent Living-Donor Liver Transplantation in a Patient With Concurrent Active Tuberculosis: A Case Report. Transplant Proc. 2018;50:910-914. [PMID: 29661461 DOI: 10.1016/j.transproceed.2018.02.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
42 Komai T, Sumitomo S, Teruya S, Fujio K. Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature. Intern Med 2018;57:2413-2416. [DOI: 10.2169/internalmedicine.0463-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
43 Russom M, Debesai M, Zeregabr M, Berhane A, Tekeste T, Teklesenbet T. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. Pharmacol Res Perspect 2018;6:e00423. [PMID: 30073087 DOI: 10.1002/prp2.423] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
44 Bhilare NV, Dhaneshwar SS, Mahadik KR. Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation. World J Hepatol 2018; 10(7): 496-508 [PMID: 30079136 DOI: 10.4254/wjh.v10.i7.496] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
45 Dipaola FW, Fontana RJ. Drug-Induced Liver Injury. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch24] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 2018;16:501-12. [PMID: 29848120 DOI: 10.1080/14787210.2018.1483238] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
47 Li AA, Dibba P, Cholankeril G, Kim D, Ahmed A. Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation. Diseases 2018;6:E40. [PMID: 29783726 DOI: 10.3390/diseases6020040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med 2018;16:46. [PMID: 29592805 DOI: 10.1186/s12916-018-1033-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
49 Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf 2018;27:557-66. [DOI: 10.1002/pds.4423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
50 Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem 2018;61:2589-603. [PMID: 29499113 DOI: 10.1021/acs.jmedchem.8b00136] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
51 Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. The Lancet Infectious Diseases 2018;18:e64-75. [DOI: 10.1016/s1473-3099(17)30623-0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 20.0] [Reference Citation Analysis]
52 McClure JJ, Li X, Chou CJ. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics. Adv Cancer Res 2018;138:183-211. [PMID: 29551127 DOI: 10.1016/bs.acr.2018.02.006] [Cited by in Crossref: 146] [Cited by in F6Publishing: 164] [Article Influence: 36.5] [Reference Citation Analysis]
53 Shehu AI, Ma X, Venkataramanan R. Mechanisms of Drug-Induced Hepatotoxicity. Clin Liver Dis. 2017;21:35-54. [PMID: 27842774 DOI: 10.1016/j.cld.2016.08.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
54 Kleiner DE. Drugs and Toxins. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 673-779. [DOI: 10.1016/b978-0-7020-6697-9.00012-1] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
55 Motamedi N, Kaplowitz N, Dara L. Clinical Considerations of Drug-Induced Hepatotoxicity. Comprehensive Toxicology 2018. [DOI: 10.1016/b978-0-12-801238-3.95665-4] [Reference Citation Analysis]
56 Zhang T, Ikejima T, Li L, Wu R, Yuan X, Zhao J, Wang Y, Peng S. Impairment of Mitochondrial Biogenesis and Dynamics Involved in Isoniazid-Induced Apoptosis of HepG2 Cells Was Alleviated by p38 MAPK Pathway. Front Pharmacol 2017;8:753. [PMID: 29123480 DOI: 10.3389/fphar.2017.00753] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
57 Effo KE, Kouakou SL, Irie-n’guessan AG, Akoubet A, Kouakou-siransy NG. Hepatoprotective effects of methanol extract of Alchornea cordifolia leaves against anti-tubercular drugs induced hepatotoxicity in rats. Afr J Pharm Pharmacol 2017;11:501-508. [DOI: 10.5897/ajpp2017.4841] [Reference Citation Analysis]
58 Kramer O, Albrecht J. Clinical presentation of terbinafine‐induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic. Br J Dermatol 2017;177:1279-84. [DOI: 10.1111/bjd.15854] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
59 Tang P, Johnston J. Treatment of Latent Tuberculosis Infection. Curr Treat Options Infect Dis 2017;9:371-9. [PMID: 29238270 DOI: 10.1007/s40506-017-0135-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
60 Chalasani N, Reddy KRK, Fontana RJ, Barnhart H, Gu J, Hayashi PH, Ahmad J, Stolz A, Navarro V, Hoofnagle JH. Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians.Am J Gastroenterol. 2017;112:1382-1388. [PMID: 28762375 DOI: 10.1038/ajg.2017.215] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
61 McMullan GS, Lewis JH. Tuberculosis of the Liver, Biliary Tract, and Pancreas. Microbiol Spectr 2017;5. [PMID: 28233514 DOI: 10.1128/microbiolspec.TNMI7-0025-2016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
62 Cojutti P, Giangreco M, Isola M, Pea F. Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. International Journal of Antimicrobial Agents 2017;50:23-8. [DOI: 10.1016/j.ijantimicag.2017.01.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
63 Dobbs TE, Webb RM. Chemotherapy of Tuberculosis. Microbiol Spectr 2017;5. [PMID: 28387179 DOI: 10.1128/microbiolspec.TNMI7-0040-2017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
64 Moon HH, Park SY, Kim JM, Park JB, Kwon CHD, Peck KR, Kim SJ, Lee SK, Joh JW. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area. Ann Transplant. 2017;22:338-345. [PMID: 28579606 DOI: 10.12659/aot.902989] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
65 Zhang T, Ikejima T, Hayashi T, Zhao J, Wang Y, Peng S. AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells: AICAR fails to alleviate INH-caused mitochondrial instability. J Appl Toxicol 2017;37:1219-24. [DOI: 10.1002/jat.3483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Balasubramanian P, Thirumalraj B, Chen S, Barathi P. Electrochemical Determination of Isoniazid Using Gallic Acid Supported Reduced Graphene Oxide. J Electrochem Soc 2017;164:H503-8. [DOI: 10.1149/2.1021707jes] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
67 Dehury S, Pattnaik KP, Kar A, Samal R, Pattnaik K. HEPATO PROTECTIVE EFFECT OF S-ADENOSYL-L-METHIONINE AGAINST ISONIAZID INDUCED HEPATITIS IN ANIMAL MODEL. jebmh 2017;4:2477-2480. [DOI: 10.18410/jebmh/2017/489] [Reference Citation Analysis]
68 Dobbs TE, Webb RM. Chemotherapy of Tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch7] [Reference Citation Analysis]
69 Haley CA. Treatment of Latent Tuberculosis Infection. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch6] [Reference Citation Analysis]
70 Mcmullan GS, Lewis JH. Tuberculosis of the Liver, Biliary Tract, and Pancreas. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch27] [Reference Citation Analysis]
71 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
72 Sung YK, Cho SK, Kim D, Won S, Choi CB, Kim TH, Jun JB, Yoo DH, Bae SC. Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. Korean J Intern Med 2018;33:1016-24. [PMID: 28288508 DOI: 10.3904/kjim.2016.214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
73 Landry JS, Menzies D. Tuberculosis Prevention. International Encyclopedia of Public Health 2017. [DOI: 10.1016/b978-0-12-803678-5.00472-0] [Reference Citation Analysis]
74 Koh C, Minns AB, Clark RF. Isoniazid and Related Hydrazines. Critical Care Toxicology 2017. [DOI: 10.1007/978-3-319-17900-1_38] [Reference Citation Analysis]
75 Manno RL, Liebowitz JE. Rheumatology. Geriatrics for Specialists 2017. [DOI: 10.1007/978-3-319-31831-8_20] [Reference Citation Analysis]
76 Dara L, Liu Z, Kaplowitz N. Pathogenesis of Idiosyncratic Drug Induced Liver Injury. Liver Pathophysiology. Elsevier; 2017. pp. 87-100. [DOI: 10.1016/b978-0-12-804274-8.00005-9] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
77 Gray EL, Goldberg HF. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection. Intern Med J 2016;46:281-7. [PMID: 26648478 DOI: 10.1111/imj.12979] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
78 Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017;64:e1-e33. [PMID: 27932390 DOI: 10.1093/cid/ciw694] [Cited by in Crossref: 241] [Cited by in F6Publishing: 260] [Article Influence: 40.2] [Reference Citation Analysis]
79 Yoshioka H, Fukaya S, Onosaka S, Nonogaki T, Nagatsu A. Kampo formula "Hochu-ekki-to" suppressed carbon tetrachloride-induced hepatotoxicity in mice. Environ Health Prev Med 2016;21:579-84. [PMID: 27709423 DOI: 10.1007/s12199-016-0571-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 2016;6:384-92. [PMID: 27709007 DOI: 10.1016/j.apsb.2016.07.014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 119] [Article Influence: 19.2] [Reference Citation Analysis]
81 Kabbara WK, Sarkis AT, Saroufim PG. Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature. Case Rep Infect Dis 2016;2016:3617408. [PMID: 27648319 DOI: 10.1155/2016/3617408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
82 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
83 Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016;63:e147-95. [PMID: 27516382 DOI: 10.1093/cid/ciw376] [Cited by in Crossref: 582] [Cited by in F6Publishing: 626] [Article Influence: 97.0] [Reference Citation Analysis]
84 Wohl DA, van Duin D. Serious infections in the elderly. Reichel's Care of the Elderly 2016. [DOI: 10.1017/cbo9781107294967.023] [Reference Citation Analysis]
85 Berkowitz FE, Severens JL, Blumberg HM. Exposure to Tuberculosis among Newborns in a Nursery: Decision Analysis for Initiation of Prophylaxis. Infect Control Hosp Epidemiol 2006;27:604-11. [DOI: 10.1086/504359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
86 Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S. Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010. Trans R Soc Trop Med Hyg 2015;109:653-9. [PMID: 26385936 DOI: 10.1093/trstmh/trv074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
87 Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis 2015;19:1039-44, i-v. [PMID: 26260821 DOI: 10.5588/ijtld.14.0829] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 7.5] [Reference Citation Analysis]
88 Zhang TG, Wang YM, Zhao J, Xia MY, Peng SQ, Ikejima T. Induction of protective autophagy against apoptosis in HepG2 cells by isoniazid independent of the p38 signaling pathway. Toxicol Res (Camb) 2016;5:963-72. [PMID: 30090405 DOI: 10.1039/c5tx00470e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
89 Schraufnagel DE. To eliminate tuberculosis, we must universally encourage treatment of its latent form. Respirology 2015;20:851-4. [PMID: 26172202 DOI: 10.1111/resp.12598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
90 Cojutti P, Duranti S, Isola M, Baraldo M, Viale P, Bassetti M, Pea F. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? J Antimicrob Chemother 2016;71:1323-9. [PMID: 26832752 DOI: 10.1093/jac/dkv490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
91 Lange C, Mandalakas AM, Kalsdorf B, Denkinger CM, Sester M. Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathog Immun 2016;1:308-29. [PMID: 28217762 DOI: 10.20411/pai.v1i2.173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
92 Mir Viladrich I, Daudén Tello E, Solano-lópez G, López Longo FJ, Taxonera Samso C, Sánchez Martínez P, Martínez Lacasa X, García Gasalla M, Dorca Sargatal J, Arias-guillén M, García García JM. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Archivos de Bronconeumología (English Edition) 2016;52:36-45. [DOI: 10.1016/j.arbr.2015.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
93 Isoniazid. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.00925-2] [Reference Citation Analysis]
94 Koh C, Minns AB, Clark RF. Isoniazid and Related Hydrazines. Critical Care Toxicology 2016. [DOI: 10.1007/978-3-319-20790-2_38-1] [Reference Citation Analysis]
95 Hopewell PC, Kato-maeda M, Ernst JD. Tuberculosis. Murray and Nadel's Textbook of Respiratory Medicine 2016. [DOI: 10.1016/b978-1-4557-3383-5.00035-x] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
96 Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015; 7(27): 2716-2728 [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
97 Lee WM. Drug-Induced Liver Disease. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch97] [Reference Citation Analysis]
98 Zazuli Z, Barliana MI, Mulyani UA, Perwitasari DA, Ng H, Abdulah R. Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients. J Clin Pharm Ther 2015;40:680-4. [PMID: 26417664 DOI: 10.1111/jcpt.12325] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
99 Wang JY, Tsai CH, Lee YL, Lee LN, Hsu CL, Chang HC, Chen JM, Hsu CA, Yu CJ, Yang PC. Gender-Dimorphic Impact of PXR Genotype and Haplotype on Hepatotoxicity During Antituberculosis Treatment. Medicine (Baltimore) 2015;94:e982. [PMID: 26091473 DOI: 10.1097/MD.0000000000000982] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
100 Riestra S, Taxonera C, Carpio D, López-san Román A, Gisbert J, Domènech E. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día 2015;14:109-19. [DOI: 10.1016/j.eii.2015.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
101 Mir Viladrich I, Daudén Tello E, Solano-López G, López Longo FJ, Taxonera Samso C, Sánchez Martínez P, Martínez Lacasa X, García Gasalla M, Dorca Sargatal J, Arias-Guillén M, García García JM. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol 2016;52:36-45. [PMID: 26187708 DOI: 10.1016/j.arbres.2015.04.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
102 Senior JR. Drug-Induced Liver Injury: Clinical and Diagnostic Aspects. Methods and Principles in Medicinal Chemistry 2015. [DOI: 10.1002/9783527673643.ch05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
104 Leeb S, Buxbaum C, Fischler B. Elevated transaminases are common in children on prophylactic treatment for tuberculosis. Acta Paediatr 2015;104:479-84. [PMID: 25619878 DOI: 10.1111/apa.12908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
105 Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM, Davern TJ, Kleiner DE, Gu J, Hoofnagle JH; US Drug-Induced Liver Injury Network Investigators. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 2015;13:1676-82.e1. [PMID: 25724701 DOI: 10.1016/j.cgh.2015.02.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
106 Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R, Migliori GB. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J 2015;45:1170-3. [PMID: 25700378 DOI: 10.1183/09031936.00216814] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
107 Eliopoulos GM, Moellering RC. Principles of Anti-infective Therapy. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00017-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00251-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
109 Si X, Jiang L, Wang X, Ding Y, Luo L. Determination of isoniazid content via cysteic acid/graphene modified glassy carbon electrode. Anal Methods 2015;7:793-8. [DOI: 10.1039/c4ay02013h] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
110 Wallace RJ, Philley JV, Griffith DE. Antimycobacterial Agents. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2015. pp. 463-478.e3. [DOI: 10.1016/b978-1-4557-4801-3.00038-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
111 Liu F, Jiao AX, Wu XR, Zhao W, Yin QQ, Qi H, Jiao WW, Xiao J, Sun L, Shen C, Tian JL, Shen D, Jacqz-Aigrain E, Shen AD. Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients. PLoS One 2014;9:e115410. [PMID: 25525805 DOI: 10.1371/journal.pone.0115410] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
112 Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, Shuster J, Fennelly KP. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis (Edinb). 2015;95:112-122. [PMID: 25595441 DOI: 10.1016/j.tube.2014.10.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
113 Kumar S, Kumar R, Dwivedi A, Pandey AK. In vitro antioxidant, antibacterial, and cytotoxic activity and in vivo effect of Syngonium podophyllum and Eichhornia crassipes leaf extracts on isoniazid induced oxidative stress and hepatic markers. Biomed Res Int. 2014;2014:459452. [PMID: 25162013 DOI: 10.1155/2014/459452] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
114 Heard K, Green JL, Anderson V, Bucher-Bartelson B, Dart RC. A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacol Toxicol 2014;15:39. [PMID: 25047090 DOI: 10.1186/2050-6511-15-39] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
115 Hazlewood GS, Naimark D, Gardam M, Bykerk V, Bombardier C. Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. Arthritis Care Res (Hoboken) 2013;65:1722-31. [PMID: 23836530 DOI: 10.1002/acr.22063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
116 Aithal GP, Larrey D. Hepatic Adverse Drug Reactions. Mann's Pharmacovigilance 2014. [DOI: 10.1002/9781118820186.ch35] [Reference Citation Analysis]
117 Sheen E, Huang RJ, Uribe LA, Nguyen MH. Isoniazid Hepatotoxicity Requiring Liver Transplantation. Dig Dis Sci 2014;59:1370-4. [DOI: 10.1007/s10620-014-3072-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Bourré-Tessier J, Arino-Torregrosa M, Choquette D. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents. Clin Rheumatol 2014;33:1049-53. [PMID: 24554383 DOI: 10.1007/s10067-014-2528-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
119 Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc 2014;3:221-7. [PMID: 26625385 DOI: 10.1093/jpids/pit089] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
120 Bergeron KG, Bonebrake RG, Gray CJ. Tuberculosis in pregnancy: current recommendations for screening and treatment in the USA. Expert Review of Anti-infective Therapy 2014;2:589-98. [DOI: 10.1586/14787210.2.4.589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
121 Piccini P, Chiappini E, Tortoli E, de Martino M, Galli L. Clinical peculiarities of tuberculosis. BMC Infect Dis 2014;14 Suppl 1:S4. [PMID: 24564419 DOI: 10.1186/1471-2334-14-S1-S4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
122 Lopez MJ, Bilhartz JL. Drug-Induced Liver Injury in Children: A Structured Approach to Diagnosis and Management. Diseases of the Liver in Children 2014. [DOI: 10.1007/978-1-4614-9005-0_19] [Reference Citation Analysis]
123 Ralph AP, Kenangalem E, Waramori G, Pontororing GJ, Sandjaja, Tjitra E, Maguire GP, Kelly PM, Anstey NM. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One 2013;8:e80302. [PMID: 24312209 DOI: 10.1371/journal.pone.0080302] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
124 Saag KG, Winthrop K, Curtis JR. Tumor Necrosis Factor, Tuberculosis, Testing, and Treatment: Teeing Up the Questions. Arthritis & Rheumatism 2013;65:1719-1721. [DOI: 10.1002/acr.22061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Dobler CC, Luu Q, Marks GB. What patient factors predict physicians' decision not to treat latent tuberculosis infection in tuberculosis contacts? PLoS One 2013;8:e76552. [PMID: 24098794 DOI: 10.1371/journal.pone.0076552] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
126 Chang AH, Polesky A, Bhatia G. House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. BMC Public Health 2013;13:894. [PMID: 24073620 DOI: 10.1186/1471-2458-13-894] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
127 Parikh ND, Levitsky J. Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis 2013;17:737-47, x-xi. [PMID: 24099028 DOI: 10.1016/j.cld.2013.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
128 Regev A. How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. Clin Liver Dis. 2013;17:749-767, xi. [PMID: 24099029 DOI: 10.1016/j.cld.2013.07.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
129 van der Have M, Oldenburg B, Fidder HH, Belderbos TD, Siersema PD, van Oijen MG. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci 2014;59:554-63. [PMID: 23949640 DOI: 10.1007/s10620-013-2820-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
130 Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis. 2013;17:609-642, ix. [PMID: 24099021 DOI: 10.1016/j.cld.2013.07.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
131 Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR; Tuberculosis Epidemiologic Studies Consortium. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect 2013;67:424-32. [PMID: 23845828 DOI: 10.1016/j.jinf.2013.07.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
132 Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28:161-167. [PMID: 23020522 DOI: 10.1111/j.1440-1746.2012.07279.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
133 Cruz AT, Ahmed A, Mandalakas AM, Starke JR. Treatment of Latent Tuberculosis Infection in Children. J Pediatric Infect Dis Soc 2013;2:248-58. [PMID: 26619479 DOI: 10.1093/jpids/pit030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
134 Gomes VF, Andersen A, Lemvik G, Wejse C, Oliveira I, Vieira FJ, Carlos LJ, Vieira Cda S, Aaby P, Gustafson P. Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study. BMJ Open 2013;3:e001545. [PMID: 23535699 DOI: 10.1136/bmjopen-2012-001545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
135 Sadatsafavi M, Marra C, Marra F, Moran O, FitzGerald JM, Lynd L. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health 2013;16:66-75. [PMID: 23337217 DOI: 10.1016/j.jval.2012.09.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
136 Tshikuka Mulumba JG, Atua Matindii B, Kilauzi AL, Mengema B, Mafuta J, Eloko Eya Matangelo G, Mukongo Bulaïmu-Lukeba A, Jerry IL. Severity of outcomes associated to types of HIV coinfection with TB and malaria in a setting where the three pandemics overlap. J Community Health 2012;37:1234-8. [PMID: 22477668 DOI: 10.1007/s10900-012-9559-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
137 Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis: LTBI diagnosis and treatment. Respirology 2013;18:205-16. [DOI: 10.1111/resp.12002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
138 Vinnard C, Gopal A, Linkin DR, Maslow J. Isoniazid Toxicity among an Older Veteran Population: A Retrospective Cohort Study. Tuberc Res Treat 2013;2013:549473. [PMID: 23365735 DOI: 10.1155/2013/549473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
139 Verma S, Kaplowitz N. Hepatotoxicity of Antitubercular Drugs. Drug-Induced Liver Disease. Elsevier; 2013. pp. 483-504. [DOI: 10.1016/b978-0-12-387817-5.00027-3] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
140 Watkins PB. Biomarkers for Drug-Induced Liver Injury. Drug-Induced Liver Disease. Elsevier; 2013. pp. 275-86. [DOI: 10.1016/b978-0-12-387817-5.00017-0] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
141 Avigan MI. Regulatory Perspectives. Drug-Induced Liver Disease. Elsevier; 2013. pp. 689-712. [DOI: 10.1016/b978-0-12-387817-5.00038-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Lucena MI, Stephens C, García-cortés M, Andrade RJ. Causality Assessment. Drug-Induced Liver Disease 2013. [DOI: 10.1016/b978-0-12-387817-5.00018-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3:37-49. [PMID: 25755470 DOI: 10.1016/j.jceh.2012.12.001] [Cited by in Crossref: 227] [Cited by in F6Publishing: 248] [Article Influence: 22.7] [Reference Citation Analysis]
144 Shin J, Hunt CM, Suzuki A, Papay JI, Beach KJ, Cheetham TC. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data: DRUG-ASSOCIATED LIVER INJURY. Pharmacoepidemiol Drug Saf 2013;22:190-8. [DOI: 10.1002/pds.3388] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
145 Norton BL, Holland DP. Current management options for latent tuberculosis: a review. Infect Drug Resist 2012;5:163-73. [PMID: 23226700 DOI: 10.2147/IDR.S29180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
146 Devarbhavi H. Adaptation and antituberculosis drug-induced liver injury. Am J Respir Crit Care Med 2012;186:387-8; author reply 388-9. [PMID: 22896595 DOI: 10.1164/ajrccm.186.4.387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
147 Tsai T, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen Y, Leonardi C; on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL, Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection: Safety of ustekinumab in psoriasis patients with latent tuberculosis. British Journal of Dermatology 2012;167:1145-52. [DOI: 10.1111/j.1365-2133.2012.11142.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
148 Lima Mde F, Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica. 2012;28:698-708. [PMID: 22488315 DOI: 10.1590/s0102-311x2012000400009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
149 Johnston VJ, Grant AD. Tuberculosis in travellers. Travel Med Infect Dis 2003;1:205-12. [PMID: 17291919 DOI: 10.1016/j.tmaid.2003.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
150 Fábrega E, Sampedro B, Cabezas J, Casafont F, Mieses MÁ, Moraleja I, Crespo J, Pons-romero F. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transpl 2012;18:1110-7. [DOI: 10.1002/lt.23480] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
151 Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE 3rd, Flynn JL. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A 2012;109:14188-93. [PMID: 22826237 DOI: 10.1073/pnas.1121497109] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 9.0] [Reference Citation Analysis]
152 Richardson RM. The diagnosis of tuberculosis in dialysis patients. Semin Dial 2012;25:419-22. [PMID: 22694662 DOI: 10.1111/j.1525-139X.2012.01093.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
153 Lighter-fisher J, Surette A. Performance of an Interferon-Gamma Release Assay to Diagnose Latent Tuberculosis Infection During Pregnancy: . Obstetrics & Gynecology 2012;119:1088-95. [DOI: 10.1097/aog.0b013e3182546aff] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
154 Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012;186:273-9. [PMID: 22561962 DOI: 10.1164/rccm.201111-2076OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
155 Fraisse P. Traitement des infections tuberculeuses latentes. Revue des Maladies Respiratoires 2012;29:579-600. [DOI: 10.1016/j.rmr.2011.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
156 White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care 2012;18:131-42. [PMID: 22419641 DOI: 10.1177/1078345811435973] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
157 Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, Phanuphak N, Buajoom R, Suwanmala P, Phanuphak P. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. AIDS Res Hum Retroviruses 2012;28:270-5. [PMID: 21899431 DOI: 10.1089/aid.2011.0041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
158 Lewis JH, Kleiner DE. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 645-760. [DOI: 10.1016/b978-0-7020-3398-8.00013-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
159 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
160 Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16. [PMID: 21772953 DOI: 10.4081/pr.2011.e16] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
161 Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011;184:590-601. [PMID: 21562129 DOI: 10.1164/rccm.201101-0181OC] [Cited by in Crossref: 105] [Cited by in F6Publishing: 116] [Article Influence: 9.5] [Reference Citation Analysis]
162 Chitturi S, Farrell GC. Drug-Induced Liver Disease. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 703-83. [DOI: 10.1002/9781119950509.ch27] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
163 Sharma S, Singh A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs 2011;20:1665-76. [PMID: 22014039 DOI: 10.1517/13543784.2011.628657] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
164 Smith BM, Menzies D. Treatment of latent TB: first do no harm. Expert Rev Anti Infect Ther 2011;9:491-3. [PMID: 21609258 DOI: 10.1586/eri.11.35] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
165 Bouchentouf R, El jastimi S, Benjelloun A, Aitbenasser MA. Hépatotoxicité des antituberculeux : épidémiologie, mécanisme et conduite à tenir. J Afr Hepato Gastroenterol 2011;5:168-173. [DOI: 10.1007/s12157-011-0270-6] [Reference Citation Analysis]
166 García-cortés M, Stephens C, Lucena MI, Fernández-castañer A, Andrade RJ. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology 2011;55:683-91. [DOI: 10.1016/j.jhep.2011.02.007] [Cited by in Crossref: 135] [Cited by in F6Publishing: 142] [Article Influence: 12.3] [Reference Citation Analysis]
167 Fraisse P. Le traitement antibiotique de l’infection tuberculeuse latente. Rationnel scientifique et régimes thérapeutiques. Journal des Anti-infectieux 2011;13:191-200. [DOI: 10.1016/j.antinf.2011.07.002] [Reference Citation Analysis]
168 Tsai T, Ho J, Song M, Szapary P, Guzzo C, Shen Y, Li S, Kim K, Kim T, Choi J, Youn J. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). Journal of Dermatological Science 2011;63:154-63. [DOI: 10.1016/j.jdermsci.2011.05.005] [Cited by in Crossref: 155] [Cited by in F6Publishing: 162] [Article Influence: 14.1] [Reference Citation Analysis]
169 Lynn Johnston B, Conly JM. Re-examining treatment of latent tuberculosis infection. Can J Infect Dis 2001;12:211-4. [PMID: 18159342 DOI: 10.1155/2001/616419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
170 Viswanatha Swamy AH, Kulkarni RV, Thippeswamy AH, Koti BC, Gore A. Evaluation of hepatoprotective activity of Cissus quadrangularis stem extract against isoniazid-induced liver damage in rats. Indian J Pharmacol 2010;42:397-400. [PMID: 21189914 DOI: 10.4103/0253-7613.71920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
171 Jafri SM, Singal AG, Kaul D, Fontana RJ. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl. 2011;17:306-314. [PMID: 21384513 DOI: 10.1002/lt.22203] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
172 Delacourt C. [Specific features of tuberculosis in childhood]. Rev Mal Respir 2011;28:529-41. [PMID: 21549907 DOI: 10.1016/j.rmr.2010.10.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
173 Seeff LB, Fontana RJ. Drug-Induced Liver Injury. Sherlock's Diseases of the Liver and Biliary System 2011. [DOI: 10.1002/9781444341294.ch24] [Reference Citation Analysis]
174 Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, Lee LN, Kao JH, Yang PC. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448-455. [PMID: 21570123 DOI: 10.1016/j.jinf.2011.04.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
175 Perriot J, Chambonnet E, Eschalier A. [Managing the adverse events of antitubercular agents]. Rev Mal Respir. 2011;28:542-555. [PMID: 21549908 DOI: 10.1016/j.rmr.2010.10.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
176 Desrochers D, González-Peralta RP, McClenathan DT, Wilsey MJ Jr, Haafiz A. Isoniazid-induced severe hepatotoxicity: an infrequent but preventable cause of liver failure in children treated for latent tuberculosis infection. Clin Med Insights Pediatr 2011;5:9-13. [PMID: 23761995 DOI: 10.4137/CMPed.S6406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
177 Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011;183:E173-9. [PMID: 21220436 DOI: 10.1503/cmaj.091824] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
178 Kanel GC, Korula J. Drug- and Toxin-Induced Liver Cell Injury. Atlas of Liver Pathology 2011. [DOI: 10.1016/b978-1-4377-0765-6.10005-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Denholm JT, McBryde ES. Management of latent tuberculosis infections in australia and new zealand: a review of current practice. Tuberc Res Treat 2010;2010:284028. [PMID: 22567257 DOI: 10.1155/2010/284028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
180 Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res 2010;11:169. [PMID: 21126375 DOI: 10.1186/1465-9921-11-169] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
181 Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am 2010;24:751-68. [PMID: 20674802 DOI: 10.1016/j.idc.2010.04.011] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 6.3] [Reference Citation Analysis]
182 Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 2010;24 Suppl 5:S29-36. [PMID: 21079425 DOI: 10.1097/01.aids.0000391019.10661.66] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
183 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010;24 Suppl 5:S57-65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 62] [Cited by in F6Publishing: 81] [Article Influence: 5.2] [Reference Citation Analysis]
184 Salinas C, Pascual Erquicia S, Diez R, Aguirre U, Egurrola M, Altube L, Capelastegui A. Pauta de tres meses de rifampicina e isoniacida para el tratamiento de la infección latente tuberculosa. Medicina Clínica 2010;135:293-9. [DOI: 10.1016/j.medcli.2010.02.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
185 Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010;7:543-556. [PMID: 20808293 DOI: 10.1038/nrgastro.2010.134] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
186 Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist 2010;3:63-72. [PMID: 21694895 DOI: 10.2147/idr.s8994] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
187 Greenaway C, Sandoe A, Vissandjee B, Kitai I, Gruner D, Wobeser W, Pottie K, Ueffing E, Menzies D, Schwartzman K; Canadian Collaboration for Immigrant and Refugee Health. Tuberculosis: evidence review for newly arriving immigrants and refugees. CMAJ 2011;183:E939-51. [PMID: 20634392 DOI: 10.1503/cmaj.090302] [Cited by in Crossref: 55] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
188 Watkins PB. Biomarkers for drug-induced liver injury. Therapy 2010;7:367-75. [DOI: 10.2217/thy.10.10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
189 Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, Chen YX, Zhou L, Zhu LZ, Gao WW. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health. 2010;10:267. [PMID: 20492672 DOI: 10.1186/1471-2458-10-267] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
190 Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, Machado Junior A, Lemos AC, Netto AR, Durovni B, Sant'Anna CC, Lima D, Capone D, Barreira D, Matos ED, Mello FC, David FC, Marsico G, Afiune JB, Silva JR, Jamal LF, Telles MA, Hirata MH, Dalcolmo MP, Rabahi MF, Cailleaux-Cesar M, Palaci M, Morrone N, Guerra RL, Dietze R, Miranda SS, Cavalcante SC, Nogueira SA, Nonato TS, Martire T, Galesi VM, Dettoni Vdo V; BTA Committee on Tuberculosis., BTA Guidelines on Tuberculosis Work Group. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol 2009;35:1018-48. [PMID: 19918635 DOI: 10.1590/s1806-37132009001000011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 134] [Article Influence: 7.7] [Reference Citation Analysis]
191 Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, Tedla Z, Motsamai OI, Kilmarx PH, Wells CD, Samandari T. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr 2010;54:71-7. [PMID: 19934764 DOI: 10.1097/QAI.0b013e3181c3cbf0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
192 Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update: Treatment of latent TB infection. Respirology 2010;15:603-22. [DOI: 10.1111/j.1440-1843.2010.01751.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 11.2] [Reference Citation Analysis]
193 Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, Samandari T. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. Am J Respir Crit Care Med. 2010;182:278-285. [PMID: 20378730 DOI: 10.1164/rccm.200911-1783oc] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
194 Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, Elwood K, Marra F, Brooks-Wilson A. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 2010;10:524-36. [PMID: 20195289 DOI: 10.1038/tpj.2010.5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
195 Bray M, Poulain C, Dougados M, Gossec L. Fréquence de prescription et tolérance du traitement antituberculeux effectué selon les recommandations nationales pour prévenir le risque de tuberculose induite par un traitement anti-TNFα. Revue du Rhumatisme 2010;77:161-168. [DOI: 10.1016/j.rhum.2010.01.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Bray M, Poulain C, Dougados M, Gossec L. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 2010;77:135-41. [DOI: 10.1016/j.jbspin.2009.10.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
197 Wallace RJ, Griffith DE. Antimycobacterial Agents. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2010. [DOI: 10.1016/b978-0-443-06839-3.00039-4] [Reference Citation Analysis]
198 ANTIBACTERIAL DRUGS. Meyler's Side Effects of Antimicrobial Drugs 2010. [DOI: 10.1016/b978-0-444-53272-5.50005-4] [Reference Citation Analysis]
199 Fitzgerald DW, Sterling TR, Haas DW. Mycobacterium tuberculosis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 3129-63. [DOI: 10.1016/b978-0-443-06839-3.00250-2] [Cited by in Crossref: 20] [Article Influence: 1.7] [Reference Citation Analysis]
200 APPENDIX. Murray and Nadel's Textbook of Respiratory Medicine 2010. [DOI: 10.1016/b978-1-4160-4710-0.00105-x] [Reference Citation Analysis]
201 Pillai SK, Eliopoulos GM, Moellering RC. Principles of Anti-infective Therapy. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 267-78. [DOI: 10.1016/b978-0-443-06839-3.00018-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
202 Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009;15:894-906. [PMID: 19642133 DOI: 10.1002/lt.21709] [Cited by in Crossref: 98] [Cited by in F6Publishing: 103] [Article Influence: 7.5] [Reference Citation Analysis]
203 Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009;10:1433-45. [PMID: 19761367 DOI: 10.2217/pgs.09.66] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
204 Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol 2010;38:142-7. [PMID: 19858501 DOI: 10.1177/0192623309351719] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
205 Yue J, Dong G, He C, Chen J, Liu Y, Peng R. Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology 2009;264:185-91. [DOI: 10.1016/j.tox.2009.08.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
206 Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review: Toxicity of first-line drugs for treatment of TB in children. Tropical Medicine & International Health 2009;14:1329-37. [DOI: 10.1111/j.1365-3156.2009.02375.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
207 Gray D, Nuttall J, Lombard C, Davies M, Workman L, Apolles P, Eley B, Cotton M, Zar H. Low Rates of Hepatotoxicity in HIV-infected Children on Anti-retroviral Therapy with and without Isoniazid Prophylaxis. Journal of Tropical Pediatrics 2010;56:159-65. [DOI: 10.1093/tropej/fmp079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
208 Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med 2009;103:1838-53. [PMID: 19682884 DOI: 10.1016/j.rmed.2009.07.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
209 Kessler M, Smith JF. Treatment of Latent Tuberculosis Infection. NeoReviews 2009;10:e396-e401. [DOI: 10.1542/neo.10-8-e396] [Reference Citation Analysis]
210 Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009;5:463-73. [PMID: 19416083 DOI: 10.1517/17425250902927386] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
211 Pisu M, Gerald J, Shamiyeh JE, Bailey WC, Gerald LB. Targeted tuberculosis contact investigation saves money without sacrificing health. J Public Health Manag Pract 2009;15:319-27. [PMID: 19525776 DOI: 10.1097/PHH.0b013e31819c3ef2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
212 Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E, Eliakim R, Eser A, Frater J. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010] [Cited by in Crossref: 371] [Cited by in F6Publishing: 352] [Article Influence: 28.5] [Reference Citation Analysis]
213 Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-60. [PMID: 19299495 DOI: 10.1164/rccm.200901-0153OC] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
214 Zabana Y, Domènech E, San Román AL, Beltrán B, Cabriada JL, Saro C, Araméndiz R, Ginard D, Hinojosa J, Gisbert JP. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008;14:1387-1391. [PMID: 18452206 DOI: 10.1002/ibd.20496] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
215 Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr. 2008;47:395-405. [PMID: 18852631 DOI: 10.1097/mpg.0b013e3181709464] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 6.9] [Reference Citation Analysis]
216 Yue J, Peng R, Chen J, Liu Y, Dong G. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacological Research 2009;59:112-9. [DOI: 10.1016/j.phrs.2008.10.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
217 Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther 2009;85:331-4. [PMID: 19129750 DOI: 10.1038/clpt.2008.262] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 5.7] [Reference Citation Analysis]
218 Reddy K, Moore D, Gilman R. Tuberculosis in Childhood and Pregnancy. Maternal and Child Health 2009. [DOI: 10.1007/b106524_14] [Reference Citation Analysis]
219 Li J, Munsiff SS, Agerton TB. Prevalence of Tuberculin Skin Test Positivity in Clinical Population in New York City. J Immigrant Minority Health 2010;12:816-22. [DOI: 10.1007/s10903-008-9204-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
220 Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008;48:1680-9. [PMID: 18853438 DOI: 10.1002/hep.22633] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 5.9] [Reference Citation Analysis]
221 Tost JR, Vidal R, Maldonado J, Caylà JA. Efectividad y tolerancia de las pautas de tratamiento antituberculoso sin isoniacida y/o rifampicina. Análisis de 85 casos. Archivos de Bronconeumología 2008;44:478-83. [DOI: 10.1016/s0300-2896(08)72117-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
222 Wu SS. Tuberculosis and hepatic toxicity in children. Pediatric Health 2008;2:463-475. [DOI: 10.2217/17455111.2.4.463] [Reference Citation Analysis]
223 Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. BMC Public Health 2008;8:201. [PMID: 18534007 DOI: 10.1186/1471-2458-8-201] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
224 Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-5. [PMID: 18508312 DOI: 10.1002/hep.22332] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
225 Marguet C, Gut-robert C, André M. Particularités du traitement de la tuberculose chez l’enfant. Revue des Maladies Respiratoires 2008;25:67-8. [DOI: 10.1016/s0761-8425(08)56025-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Fraisse P. Démarches diagnostique et thérapeutique devant un contage tuberculeux. EMC - Traité de médecine AKOS 2008;3:1-16. [DOI: 10.1016/s1634-6939(08)34172-6] [Reference Citation Analysis]
227 Fraisse P. Iter diagnostico e terapeutico di fronte a un contagio tubercolare. EMC - AKOS - Trattato di Medicina 2008;10:1-15. [DOI: 10.1016/s1634-7358(08)70363-2] [Reference Citation Analysis]
228 Haulman NJ, Hawn TR, Nolan CM. Tuberculosis in Travelers and Immigrants. The Travel and Tropical Medicine Manual 2008. [DOI: 10.1016/b978-141602613-6.10024-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
229 Landry J, Menzies D. Tuberculosis Prevention. International Encyclopedia of Public Health 2008. [DOI: 10.1016/b978-012373960-5.00222-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
230 Tost JR, Vidal R, Maldonado J, Caylà JA. Effectiveness and Tolerance of Antituberculosis Treatment Regimens Without Isoniazid and Rifampicin: Analysis of 85 Cases. Archivos de Bronconeumología ((English Edition)) 2008;44:478-483. [DOI: 10.1016/s1579-2129(08)60086-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6:673-684. [PMID: 17967156 DOI: 10.1517/14740338.6.6.673] [Cited by in Crossref: 126] [Cited by in F6Publishing: 135] [Article Influence: 8.4] [Reference Citation Analysis]
232 Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008;133:862-8. [PMID: 18071014 DOI: 10.1378/chest.07-2024] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
233 Marschall H, Wagner M, Zollner G, Trauner M. Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. Mol Pharmaceutics 2007;4:895-910. [DOI: 10.1021/mp060133c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
234 Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007;11:507-24, vi. [PMID: 17723917 DOI: 10.1016/j.cld.2007.06.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 3.8] [Reference Citation Analysis]
235 Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192-202. [PMID: 17995946 DOI: 10.1111/j.1440-1746.2007.05207.x] [Cited by in Crossref: 432] [Cited by in F6Publishing: 465] [Article Influence: 28.8] [Reference Citation Analysis]
236 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007;196 Suppl 1:S52-62. [PMID: 17624827 DOI: 10.1086/518662] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
237 Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007;30:277-294. [PMID: 17408305 DOI: 10.2165/00002018-200730040-00001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 225] [Article Influence: 14.1] [Reference Citation Analysis]
238 Schlossberg D, Pritchett EN, Nnumolu C. Asymptomatic Hepatotoxicity in Patients Treated for Tuberculosis and Latent Tuberculosis. Infectious Diseases in Clinical Practice 2007;15:320-323. [DOI: 10.1097/ipc.0b013e3181373d3a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
239 Wu SS, Chao CS, Vargas JH, Sharp HL, Martín MG, Mcdiarmid SV, Sinatra FR, Ament ME. Isoniazid-Related Hepatic Failure in Children: A Survey of Liver Transplantation Centers. Transplantation 2007;84:173-9. [DOI: 10.1097/01.tp.0000269104.22502.d2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.2] [Reference Citation Analysis]
240 Jahng AW, Tran T, Bui L, Joyner JL. Safety of Treatment of Latent Tuberculosis Infection in Compensated Cirrhotic Patients During Transplant Candidacy Period. Transplantation 2007;83:1557-62. [DOI: 10.1097/01.tp.0000266578.45634.4f] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
241 Tavil B, Gulhan B, Ozcelik U, Cetin M, Tezcan I, Tuncer M, Uckan D. Tuberculin skin test positivity in pediatric allogeneic BMT recipients and donors in Turkey. Pediatric Transplantation 2007;11:414-8. [DOI: 10.1111/j.1399-3046.2007.00679.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
242 Efferen LS. Tuberculosis and pregnancy: . Current Opinion in Pulmonary Medicine 2007;13:205-11. [DOI: 10.1097/mcp.0b013e3280f6ceee] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
243 Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of Interferon-γ Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany. Chest 2007;131:1424-34. [DOI: 10.1378/chest.06-2728] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
244 Aouam K, Chaabane A, Loussaïef C, Ben Romdhane F, Boughattas N, Chakroun M. Les effets indésirables des antituberculeux: épidémiologie, mécanismes et conduite à tenir. Médecine et Maladies Infectieuses 2007;37:253-61. [DOI: 10.1016/j.medmal.2006.12.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
245 Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forné M, Solà R, Castellote J, Rigau J, Laporte J. Risk of acute liver injury associated with the use of drugs: a multicentre population survey: DRUG-INDUCED LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2007;25:1401-9. [DOI: 10.1111/j.1365-2036.2007.03338.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
246 Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11:699-707. [PMID: 17052297 DOI: 10.1111/j.1440-1843.2006.00941.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 171] [Article Influence: 10.5] [Reference Citation Analysis]
247 McCarthy FP, Rowlands S, Giles M. Tuberculosis in pregnancy - case studies and a review of Australia's screening process. Aust N Z J Obstet Gynaecol 2006;46:451-5. [PMID: 16953862 DOI: 10.1111/j.1479-828X.2006.00633.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
248 Geib A, Shannon MW. Isoniazid. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose 2007. [DOI: 10.1016/b978-0-7216-0693-4.50060-8] [Reference Citation Analysis]
249 Swaminathan S. 30 Drugs used in tuberculosis and leprosy. Side Effects of Drugs Annual 2007. [DOI: 10.1016/s0378-6080(06)29030-5] [Reference Citation Analysis]
250 Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521-90. [PMID: 16968950 DOI: 10.1124/pr.58.3.6] [Cited by in Crossref: 280] [Cited by in F6Publishing: 294] [Article Influence: 17.5] [Reference Citation Analysis]
251 Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935-952. [PMID: 17021358 DOI: 10.1164/rccm.200510-1666st] [Cited by in Crossref: 669] [Cited by in F6Publishing: 711] [Article Influence: 41.8] [Reference Citation Analysis]
252 Kominski GF, Varon SF, Morisky DE, Malotte CK, Ebin VJ, Coly A, Chiao C. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health 2007;40:61-8. [PMID: 17185207 DOI: 10.1016/j.jadohealth.2006.08.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
253 Senior JR. How can 'Hy's law' help the clinician? Pharmacoepidemiol Drug Saf 2006;15:235-9. [PMID: 16552792 DOI: 10.1002/pds.1210] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
254 Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 2006;6:157. [PMID: 16784541 DOI: 10.1186/1471-2458-6-157] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
255 Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231-249. [PMID: 16503745 DOI: 10.1517/14740338.5.2.231] [Cited by in Crossref: 159] [Cited by in F6Publishing: 202] [Article Influence: 9.9] [Reference Citation Analysis]
256 Mcelroy PD, Ijaz K, Navin TR. Reply to Cook. Clinical Infectious Diseases 2006;42:892-893. [DOI: 10.1086/500462] [Reference Citation Analysis]
257 Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkekol FO, Baççioğlu A, Acican T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006;100:1834-42. [PMID: 16517138 DOI: 10.1016/j.rmed.2006.01.014] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 5.4] [Reference Citation Analysis]
258 Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006;174:635-41. [PMID: 16505459 DOI: 10.1503/cmaj.050873] [Cited by in Crossref: 149] [Cited by in F6Publishing: 155] [Article Influence: 9.3] [Reference Citation Analysis]
259 Sackoff JE, Pfeiffer MR, Driver CR, Streett LS, Munsiff SS, DeHovitz JA. Tuberculosis prevention for non-US-born pregnant women. Am J Obstet Gynecol 2006;194:451-6. [PMID: 16458645 DOI: 10.1016/j.ajog.2005.07.054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
260 Menzies D. Mycobacterium tuberculosis as a Cause of Community-Acquired Pneumonia. Community-Acquired Pneumonia. [DOI: 10.1007/0-306-46834-4_48] [Reference Citation Analysis]
261 Isoniazid. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions 2006. [DOI: 10.1016/b0-44-451005-2/00792-0] [Reference Citation Analysis]
262 . BS, . HK, . MS. Incidence of Hepatotoxicity Due to Antitubercular Medicine and Assessment of Risk Factors, Zahedan, Iran. J of Medical Sciences 2005;6:44-47. [DOI: 10.3923/jms.2006.44.47] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}. Ann Rheum Dis 2005;64 Suppl 4:iv29-30. [PMID: 16239382 DOI: 10.1136/ard.2005.042390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
264 Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745-52. [DOI: 10.1111/j.1440-1746.2005.04048.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.3] [Reference Citation Analysis]
265 Coleman JJ, Mcdowell SE. Ethnicity and adverse drug reactions. Adverse Drug Reaction Bulletin 2005;&NA;:899-902. [DOI: 10.1097/00012995-200510000-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
266 Dworkin MS, Adams MR, Cohn DL, Davidson AJ, Buskin S, Horwitch C, Morse A, Sackoff J, Thompson M, Wotring L, McCombs SB, Jones JL. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005;39:464-70. [PMID: 16010171 DOI: 10.1097/01.qai.0000152400.36723.85] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
267 McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, Navin TR. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33. [PMID: 16163632 DOI: 10.1086/444463] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
268 Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116-123. [PMID: 16002924 DOI: 10.1378/chest.128.1.116] [Cited by in Crossref: 176] [Cited by in F6Publishing: 188] [Article Influence: 10.4] [Reference Citation Analysis]
269 British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5. [PMID: 16055611 DOI: 10.1136/thx.2005.046797] [Cited by in Crossref: 328] [Cited by in F6Publishing: 350] [Article Influence: 19.3] [Reference Citation Analysis]
270 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489-499. [PMID: 15931258 DOI: 10.1038/nrd1750] [Cited by in Crossref: 777] [Cited by in F6Publishing: 800] [Article Influence: 45.7] [Reference Citation Analysis]
271 Zhou S, Chan E, Duan W, Huang M, Chen YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005;37:41-213. [PMID: 15747500 DOI: 10.1081/dmr-200028812] [Cited by in Crossref: 187] [Cited by in F6Publishing: 197] [Article Influence: 11.0] [Reference Citation Analysis]
272 Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005;33:155-164. [PMID: 15805067 DOI: 10.1080/01926230590522356] [Cited by in Crossref: 138] [Cited by in F6Publishing: 111] [Article Influence: 8.1] [Reference Citation Analysis]
273 Sahbazian B, Weis SE. Treatment of Active Tuberculosis: Challenges and Prospects. Clinics in Chest Medicine 2005;26:273-82. [DOI: 10.1016/j.ccm.2005.02.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
274 Dooley KE, Sterling TR. Treatment of Latent Tuberculosis Infection: Challenges and Prospects. Clinics in Chest Medicine 2005;26:313-26. [DOI: 10.1016/j.ccm.2005.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
275 Martínez Sanchís A, Calpe Calpe JL, Llavador Ros G, Ena Muñoz J, Calpe Armero A. [Primary prevention and treatment of latent tuberculosis infection with isoniazid: efficacy of a control program, 1997-2002]. Arch Bronconeumol 2005;41:27-33. [PMID: 15676133 DOI: 10.1016/s1579-2129(06)60391-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
276 Thrupp L, Bradley S, Smith P, Simor A, Gantz N, Crossley K, Loeb M, Strausbaugh L, Nicolle L; SHEA Long-Term-Care Committee. Tuberculosis prevention and control in long-term-care facilities for older adults. Infect Control Hosp Epidemiol 2004;25:1097-108. [PMID: 15636299 DOI: 10.1086/502350] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
277 Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety 2005;3:187-98. [DOI: 10.1517/14740338.3.3.187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
278 Martínez Sanchís A, Calpe Calpe J, Llavador Ros G, Ena Muñoz J, Calpe Armero A. Prevención primaria y tratamiento de la infección tuberculosa latente con isoniacida: eficacia de un programa de control, 1997-2002. Archivos de Bronconeumología 2005;41:27-33. [DOI: 10.1157/13070281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
279 Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA. Use of Intermittent Rifampin and Pyrazinamide Therapy for Latent Tuberculosis Infection in a Targeted Tuberculin Testing Program. Clinical Infectious Diseases 2004;39:1764-71. [DOI: 10.1086/425610] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
280 Blumberg HM. Treatment of Latent Tuberculosis Infection: Back to the Beginning. Clinical Infectious Diseases 2004;39:1772-5. [DOI: 10.1086/425620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
281 Kraut A, Coodin M, Plessis R, Mclean D. Predictors of Positive Tuberculin Skin Test (TST) Results after 2‐Step TST among Health Care Workers in Manitoba, Canada. CLIN INFECT DIS 2004;39:e113-8. [DOI: 10.1086/425916] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
282 Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018-1023. [PMID: 15390328 DOI: 10.1002/lt.20204] [Cited by in Crossref: 333] [Cited by in F6Publishing: 354] [Article Influence: 18.5] [Reference Citation Analysis]
283 Peter Ormerod L. Assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFα treatment. Cytokine 2004;28:179-81. [DOI: 10.1016/j.cyto.2004.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
284 Lerman SJ, Bernardo J, Daly JS, Husson R. Tuberculosis prevention in college students. J Am Coll Health 2004;53:53-8. [PMID: 15495880 DOI: 10.3200/JACH.53.2.53-58] [Reference Citation Analysis]
285 Reichman LB, Lardizabal A, Hayden CH. Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection. Am J Respir Crit Care Med 2004;170:832-5. [DOI: 10.1164/rccm.200405-584pp] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
286 Delacourt C, Albertini M, Decludt B, Scheinmann P, Marguet C. [What examinations are necessary in an exposed, asymptomatic child with a positive tuberculin skin test and normal chest x-ray?]. Rev Mal Respir 2004;21:S13-23. [PMID: 15344265 DOI: 10.1016/s0761-8425(04)71380-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
287 van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, Keizer S, Borgdorff M, Mensen M, Cobelens F. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39:488-496. [PMID: 15356811 DOI: 10.1086/422645] [Cited by in Crossref: 75] [Cited by in F6Publishing: 84] [Article Influence: 4.2] [Reference Citation Analysis]
288 Ijaz K, Mcelroy PD, Navin TR. Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost-Effectiveness Analysis Based on a Multicenter Clinical Trial. Clinical Infectious Diseases 2004;39:289-289. [DOI: 10.1086/421783] [Reference Citation Analysis]
289 Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-9. [PMID: 15172892 DOI: 10.1164/rccm.200404-478OC] [Cited by in Crossref: 110] [Cited by in F6Publishing: 121] [Article Influence: 6.1] [Reference Citation Analysis]
290 Deschildre A, Poirier C, Cadranel J. Dans quelles circonstances et comment traiter une infection tuberculeuse latente ? Revue des Maladies Respiratoires 2004;21:25-34. [DOI: 10.1016/s0761-8425(04)71381-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
291 Fraisse P. Dans une population tout-venant d’infections tuberculeuses latentes, l’hépato-toxicité d’une monothérapie par isoniazide est rare (0,3 %). Revue des Maladies Respiratoires 2004;21:134-136. [DOI: 10.1016/s0761-8425(04)72031-8] [Reference Citation Analysis]
292 Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 2004;39:1204-12. [PMID: 15122748 DOI: 10.1002/hep.20169] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
293 Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheumatic Disease Clinics of North America 2004;30:257-70. [DOI: 10.1016/j.rdc.2004.01.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
294 Cadranel J, Delacourt C. Diagnostic et traitement de l’infection tuberculeuse latente : un texte qui doit être clarifié pour le rendre applicable. Revue des Maladies Respiratoires 2004;21:255-8. [DOI: 10.1016/s0761-8425(04)71283-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
295 Berg J, Blumberg EJ, Sipan CL, Friedman LS, Kelley NJ, Vera AY, Hofstetter CR, Hovell MF. Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI). Patient Educ Couns 2004;52:31-9. [PMID: 14729288 DOI: 10.1016/s0738-3991(02)00268-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
296 Scholten JN, Driver CR, Munsiff SS, Kaye K, Rubino MA, Gourevitch MN, Trim C, Amofa J, Seewald R, Highley E, Fujiwara PI. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 2003;37:1686-92. [PMID: 14689352 DOI: 10.1086/379513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
297 Nolan CM. Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime. Am J Respir Crit Care Med 2003;168:412-3. [PMID: 12912731 DOI: 10.1164/rccm.2306004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
298 Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*: . JAIDS Journal of Acquired Immune Deficiency Syndromes 2003;34:S21-33. [DOI: 10.1097/00126334-200309011-00005] [Cited by in Crossref: 153] [Cited by in F6Publishing: 160] [Article Influence: 8.1] [Reference Citation Analysis]
299 Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003;7:381-99, vi-vii. [PMID: 12879990 DOI: 10.1016/s1089-3261(03)00021-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
300 Lobue PA, Moser KS. Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic. Am J Respir Crit Care Med 2003;168:443-7. [DOI: 10.1164/rccm.200303-390oc] [Cited by in Crossref: 152] [Cited by in F6Publishing: 161] [Article Influence: 8.0] [Reference Citation Analysis]
301 Chaisson RE. Tuberculosis Chemotherapy: Still a Double-edged Sword. Am J Respir Crit Care Med 2003;167:1461-2. [DOI: 10.1164/rccm.2303004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
302 Zevallos M, Justman JE. Tuberculosis in the elderly. Clin Geriatr Med 2003;19:121-38. [PMID: 12735118 DOI: 10.1016/s0749-0690(02)00057-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 3.0] [Reference Citation Analysis]
303 Vinholt Schiødt F, Lee WM. Fulminant liver disease. Clinics in Liver Disease 2003;7:331-49. [DOI: 10.1016/s1089-3261(03)00026-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
304 Hersh AL, Tosteson AN, von Reyn C. Dual skin testing for latent tuberculosis infection. American Journal of Preventive Medicine 2003;24:254-9. [DOI: 10.1016/s0749-3797(02)00584-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
305 Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. [PMID: 12588714 DOI: 10.1164/rccm.167.4.603] [Cited by in Crossref: 1363] [Cited by in F6Publishing: 1446] [Article Influence: 71.7] [Reference Citation Analysis]
306 Jasmer RM, Daley CL. Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection: Is It Safe? Am J Respir Crit Care Med 2003;167:809-10. [DOI: 10.1164/rccm.2301002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
307 Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis. Am J Respir Crit Care Med 2003;167:824-7. [DOI: 10.1164/rccm.200209-998oc] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 3.1] [Reference Citation Analysis]
308 Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472-1477. [PMID: 12569078 DOI: 10.1164/rccm.200206-626oc] [Cited by in Crossref: 500] [Cited by in F6Publishing: 537] [Article Influence: 26.3] [Reference Citation Analysis]
309 Fernández-Villar A, Sopeña B, Vázquez R, Ulloa F, Fluiters E, Mosteiro M, Martínez-Vázquez C, Piñeiro L. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003;36:293-8. [PMID: 12539070 DOI: 10.1086/345906] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
310 Rodnick JE, Gude JK. Pulmonary Infections. Family Medicine 2003. [DOI: 10.1007/978-0-387-21744-4_84] [Reference Citation Analysis]
311 Sanford C. Pre-travel advice: an overview. Primary Care: Clinics in Office Practice 2002;29:767-85. [DOI: 10.1016/s0095-4543(02)00046-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
312 Benito N, Sued O, Moreno A, Pablo Horcajada J, Gonz??lez J, Navasa M, Rimola A. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area: . Transplantation 2002;74:1381-6. [DOI: 10.1097/00007890-200211270-00006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 3.9] [Reference Citation Analysis]
313 Orenstein R, Tsogas N. Looking Beyond Highly Active Antiretroviral Therapy: Drug-Related Hepatotoxicity in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy 2002;22:1468-78. [DOI: 10.1592/phco.22.16.1468.33702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
314 Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002;97:1198-203. [PMID: 12014728 DOI: 10.1111/j.1572-0241.2002.05704.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 2.7] [Reference Citation Analysis]
315 Nguyen MH, Garcia G. Does isoniazid cause more serious hepatotoxicity in hepatitis B virus carriers? Am J Gastroenterol 2002;97:1092-3. [PMID: 12014711 DOI: 10.1111/j.1572-0241.2002.05700.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
316 Rieder H. Risk of Travel‐Associated Tuberculosis. CLIN INFECT DIS 2001;33:1393-6. [DOI: 10.1086/323127] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.2] [Reference Citation Analysis]
317 Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33:1687-1691. [PMID: 11641824 DOI: 10.1086/323896] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.0] [Reference Citation Analysis]
318 Roz˘manić V, Kilvain S, Ahel V, Banac S, Gazdik M. Pulmonary tuberculosis with gallbladder involvement: A review and case report. Pediatrics International 2001;43:511-3. [DOI: 10.1046/j.1442-200x.2001.01435.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
319 Burman W, Reves R. Hepatotoxicity from Rifampin Plus Pyrazinamide: Lessons for Policymakers and Messages for Care Providers. Am J Respir Crit Care Med 2001;164:1112-3. [DOI: 10.1164/ajrccm.164.7.2109052] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
320 Wallis RS, Johnson JL. Adult tuberculosis in the 21st century: pathogenesis, clinical features, and management: . Current Opinion in Pulmonary Medicine 2001;7:124-32. [DOI: 10.1097/00063198-200105000-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
321 Hirsch CS, Johnson JL. Treatment of Latent Tuberculosis Infection: New U.S. Guidelines. Infectious Disease in Clinical Practice 2001;10:93-99. [DOI: 10.1097/00019048-200102000-00005] [Reference Citation Analysis]
322 Ellis C. Drugs used in tuberculosis and leprosy. Side Effects of Drugs Annual 2001. [DOI: 10.1016/s0378-6080(01)80035-0] [Reference Citation Analysis]
323 Boggess KA, Myers ER, Hamilton CD. Antepartum or Postpartum Isoniazid Treatment of Latent Tuberculosis Infection. Obstetrics & Gynecology 2000;96:757-762. [DOI: 10.1097/00006250-200011000-00021] [Reference Citation Analysis]
324 Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84:1275-1311, x. [PMID: 11026929 DOI: 10.1016/s0025-7125(05)70287-x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 74] [Article Influence: 4.2] [Reference Citation Analysis]
325 Gilroy SA, Rogers MAM, Blair DC. Treatment of Latent Tuberculosis Infection in Patients Aged ≥35 Years. Clinical Infectious Diseases 2000;31:826-9. [DOI: 10.1086/314037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
326 Cohn DL. Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis Control. Clinical Infectious Diseases 2000;31:120-4. [DOI: 10.1086/313891] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
327 Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221-S247. [PMID: 10764341 DOI: 10.1164/ajrccm.161.supplement_3.ats600] [Cited by in Crossref: 816] [Cited by in F6Publishing: 966] [Article Influence: 37.1] [Reference Citation Analysis]
328 Johnson JL, Ellner JJ. Adult tuberculosis overview: African versus Western perspectives: . Current Opinion in Pulmonary Medicine 2000;6:180-6. [DOI: 10.1097/00063198-200005000-00003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
329 Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol. 1999;31:1098-1105. [PMID: 10604586 DOI: 10.1016/s0168-8278(99)80325-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
330 Waiser J, Schötschel R, Budde K, Neumayer H. Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. American Journal of Kidney Diseases 2000;35:e12.1-5. [DOI: 10.1016/s0272-6386(00)70224-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
331 Osmon DR. Antimicrobial Prophylaxis in Adults. Mayo Clinic Proceedings 2000;75:98-109. [DOI: 10.4065/75.1.98] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
332 . Documento de Consenso sobre tratamientos directamente observados en tuberculosis. Medicina Clínica 2000;115:749-57. [DOI: 10.1016/s0025-7753(00)71680-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
333 &NA;. Low risk of hepatotoxicity with isoniazid. Reactions Weekly 1999;&NA;:5. [DOI: 10.2165/00128415-199907440-00011] [Reference Citation Analysis]